| Page 1840 | Kisaco Research
 

Dr. Ulrich Thienel

Chief Medical Officer
Finch Therapeutics Group

Dr. Ulrich Thienel

Chief Medical Officer
Finch Therapeutics Group

Dr. Ulrich Thienel

Chief Medical Officer
Finch Therapeutics Group
 

Dr. Greg Gloor

Department of Biochemistry
The University of Western Ontario

Dr. Greg Gloor

Department of Biochemistry
The University of Western Ontario

Dr. Greg Gloor

Department of Biochemistry
The University of Western Ontario
 

Dr Gemma Owens

Clinical Research Fellow and Specialist Registrar
Clinical and Experimental Immunotherapy Group, Division of Cancer Sciences, University of Manchester

Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches.

Dr Gemma Owens

Clinical Research Fellow and Specialist Registrar
Clinical and Experimental Immunotherapy Group, Division of Cancer Sciences, University of Manchester

Dr Gemma Owens

Clinical Research Fellow and Specialist Registrar
Clinical and Experimental Immunotherapy Group, Division of Cancer Sciences, University of Manchester

Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches. In collaboration with Oxford Biomedica, Gemma has demonstrated that 5T4 is an attractive target for CAR-T cell therapy in ovarian cancer.

AgbioInvestor R&D in 2017 Infographic
 

Massimo Mazorati

CEO
Prodigest

Massimo Mazorati

CEO
Prodigest

Massimo Mazorati

CEO
Prodigest
 

Mike Frodsham

Pharmaceutical Development Manager
Quay Pharma

Mike Frodsham

Pharmaceutical Development Manager
Quay Pharma

Mike Frodsham

Pharmaceutical Development Manager
Quay Pharma
 

Dr Morten L. Isaksen

CEO
Bio-Me As

Dr Morten L. Isaksen

CEO
Bio-Me As

Dr Morten L. Isaksen

CEO
Bio-Me As
 

Dr Hue-Tran Hornig-Do

Scientific Communication Manager
Jennewin Biotechnologie

Dr Hue-Tran Hornig-Do

Scientific Communication Manager
Jennewin Biotechnologie

Dr Hue-Tran Hornig-Do

Scientific Communication Manager
Jennewin Biotechnologie
 

Sebastien Guery

Human Microbiome Venture Leader
Dupont Nutrition and Health

Sebastien Guery

Human Microbiome Venture Leader
Dupont Nutrition and Health

Sebastien Guery

Human Microbiome Venture Leader
Dupont Nutrition and Health